Twist Bioscience Corporation (TWST) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Diagnostics & Research industria. La empresa tiene su sede en South San Francisco, CA, United States. El CEO actual es Emily Marine Leproust.
TWST tiene fecha de IPO 2018-10-31, 923 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.52B.
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells synthetic DNA-based products using its proprietary DNA synthesis platform, which writes DNA directly onto silicon chips. The company offers a diverse portfolio including synthetic genes, sample preparation tools, antibody libraries for drug discovery, and DNA-based digital data storage solutions. Twist has established strategic collaborations with leading pharmaceutical and biotechnology firms such as Boehringer Ingelheim, Kyowa Kirin, and Centogene to advance sequencing tools and therapeutic antibody discovery. Founded in 2013 and headquartered in South San Francisco, California, the company serves the pharmaceutical, diagnostics, and data storage industries.
